Checkout the New Issue of Countdown!
We are pleased to announce that the newest edition of Countdown is now available online. This issue features tips from medical practitioners, research highlights, and stories of JDRF around the world. Read along to learn more about the featured articles and research highlights.
In this issue:
· Lucentis for Diabetic Eye Disease: Genentech, Inc., a member of the Roche Group, announced that its second Phase III study known as RISE, which is evaluating the drug Lucentis in patients with diabetic macular edema, met its primary clinical endpoint.
· Key Enzyme Boosts Beta Cell Numbers: JDRF-funded researchers have identified a key signal that prompts existing beta cells, the only cells in the body that produce the hormone insulin, to form new beta cells. Their breakthrough discovery may ultimately be used to develop new treatments that will help to increase the number or function of beta cells in people with type 1 diabetes.
· New NIH Prevention Trial Targets Very High-Risk Relatives: A new clinical trial through TrialNet, a multi-center consortium sponsored by the National Institutes of Health, will be testing a drug’s efficacy in stopping the progression of type 1 diabetes in high-risk relatives of people currently diagnosed with the disease.
· Researchers Use Patient’s Own Immune Cells to Keep Type 1 Diabetes in Check: Researchers at the University of California, San Francisco (UCSF) are conducting a Phase I clinical trial using a patient’s own immune cells to halt or reverse the course of type 1 diabetes for those recently diagnosed with the disease.
· Beta Cell Encapsulation Workshop: On March 22-23, 2011, JDRF brought together more than 40 corporate and academic experts on beta cell encapsulation in order to discuss the most recent progress, and to identify critical gaps, in the field. Recommendations from the workshop will guide JDRF’s next wave of research efforts to close these gaps and move the field forward.
· Know Your Numbers: This article gives guidelines to help you learn about your body, your diabetes, and your best options for a long and healthy life.
· Preventing Type 1 Diabetes: The Leadership Role of JDRF: Read this article to learn about JDRF’s leadership roles. As JDRF remains steadfast in its mission of curing type 1 diabetes, we are also committed to both improving treatments for individuals with the disease as well as preventing the disorder itself.
· Traveling with Diabetes: Whether you are driving through the back country of Utah or jet-setting to an island in French Polynesia, here are some tips to help you plan for a great getaway!
· Vaccines: Tackling The Root Cause of Type 1 Diabetes: this article describes how new insights into the workings of the immune system and how it interacts with beta cells have given scientists an unprecedented vantage point from which to develop a diabetes vaccine.
To learn more about the JDRF Dallas chapter, visit our JDRF Dallas website!